Clinical trials: Liver Inflammation
Hepatitis C
GS-7977 With Ribavirin for Hepatitis C (SPARE)
Background: GS-7977 is a new drug that is being developed to treat hepatitis C infection. It works by blocking the hepatitis C virus from dividing in the body.
- Trial name
- NCT01441180
- Testing
- GS7977, RBV
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Substance Use Disorders
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
hepatitis C virus (HCV) has traditionally been treated in subspecialty health centers given the complexity of older pegylated interferon containing regimens, formerly the standard of care.
- Conditions
- Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
- Trial name
- NCT03093415
- Testing
- elbasvir-grazoprevir (50 mg/100 mg)
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oregon Health and Science University
Hepatitis C, Chronic
Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)
The primary objective is to assess the safety, efficacy and tolerability of the combination of PEG-Intron plus REBETOL in pediatric subjects with chronic hepatitis C.
- Trial name
- NCT00104052
- Testing
- peginterferon alfa-2b (PEG2b) (SCH 54031), ribavirin (SCH 18908)
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B, Chronic
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine whether ARC-520 in combination with entecavir is effective in the treatment of patients with chronic HBV Infection.
- Trial name
- NCT02065336
- Testing
- ARC-520, entecavir, chlorpheniramine
- Where
- 2 sites in Hong Kong
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis C
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and Ribavirin (RBV) in patients with genotype 2 hepatitis C, who relapsed after previous treatment.
- Trial name
- NCT01466192
- Testing
- MP-424 (generic name:Telaprevir), Ribavirin, Peginterferon alfa-2b
- Where
- Japan
- Volunteers
- 108 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis C, Chronic, Lung Transplant
Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment
The purpose of this study is to evaluate whether treatment with Epclusa (sofosbuvir/velpatasvir) after lung transplantation in individuals with chronic hepatitis C infection is feasible, safe and effective at curing HCV.
- Trial name
- NCT03207399
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Hepatitis C
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
- Trial name
- NCT00136214
- Testing
- MR brain and neuropsychiatric tests
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic HCV Infection
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with genotypes 1 and 4 hepatitis…
- Trial name
- NCT02120300
- Testing
- LDV/SOF, SOF, RBV
- Where
- 13 sites in United States
- Volunteers
- 122 people
- Sponsor
- Gilead Sciences
Hepatitis B, Hepatitis A
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 6, 7, 8, 9 and 10 after subjects received their first two doses primary vaccination schedule of combined hepatitis…
- Trial name
- NCT00289744
- Testing
- TWINRIX™ ADULT, Engerix TM
- Where
- Belgium
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV-1-infection, Hepatitis B
B/F/TAF Switch Study for HIV-HBV Coinfection
The primary objective of this study is to evaluate the efficacy and safety of fixed dose combination (FDC) bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults coinfected with both HIV-1 and hepatitis B.
- Trial name
- BEST-HBV (NCT03797014)
- Testing
- B/F/TAF
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Maryland, Baltimore
Chronic Hepatitis C
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
To address the need for more affordable hepatitis C virus (HCV) antivirals with high barriers to viral resistance and strategies to shorten the current treatment duration, the goal is to develop affordable therapeutic regimens to…
- Trial name
- NCT02971033
- Testing
- 20mg ezetimibe, 40mg ezetimibe
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
This was a single center, open-label, single-arm study in which approximately 28 Hepatitis A virus (HAV)-seronegative healthy subjects were enrolled.
- Trial name
- GamaSTAN (NCT03351933)
- Testing
- Immune Globulin (Human)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Grifols Therapeutics LLC
Alcoholic Hepatitis (AH)
Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997) in combination with prednisolone versus prednisolone alone in participants with severe alcoholic hepatitis (AH).
- Trial name
- NCT02854631
- Testing
- Selonsertib, Prednisolone
- Where
- 44 sites in United States, Austria and 5 more
- Volunteers
- 104 people
- Sponsor
- Gilead Sciences
Biliary Tract Neoplasms, Cholangiocarcinoma
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Background: Biliary tract cancers are rare but they are serious. Researchers want to see if a certain drug helps the immune system fight cancer cells. The drug is called pembrolizumab.
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer
- Trial name
- NCT03111732
- Testing
- Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Chronic
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a [Pegasys] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on…
- Trial name
- NCT01087944
- Testing
- Autoinjector, Pre-filled syringe
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, HIV Infections
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV…
- Trial name
- NCT00983853
- Testing
- peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 62 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Tetanus, Diphtheria
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine co-administered with GSK Biologicals' 10-valent pneumococcal conjugate (GSK1024850A) vaccine given as a three-dose primary vaccination…
- Conditions
- Tetanus, Diphtheria, Haemophilus Influenzae Type b, Poliomyelitis
- Trial name
- NCT00970307
- Testing
- GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™
- Where
- 9 sites in Poland
- Volunteers
- 421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
The main purpose of this study is to evaluate efficacy of 24 weeks of study treatment, in terms of changes in hepatitis B surface antigen (HBsAg) levels.
- Trial name
- NCT03361956
- Testing
- JNJ-56136379, NA (ETV or TDF)
- Where
- 76 sites in United States, Belgium and 17 more
- Volunteers
- 232 people
- Sponsor
- Janssen Sciences Ireland UC
Liver Transplant, Hepatitis C
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
This is an open-label, pilot trial to test the safety and efficacy of transplantation of livers from Hepatitis C seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative…
- Trial name
- NCT03819322
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fernanda P Silveira, MD, MS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.